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ARTICLE
Patients with sickle cell disease are frequently 
excluded from the benefits of transcranial 
doppler screening for the risk of stroke despite 
extensive and compelling evidence
Pacientes com doença falciforme são frequentemente excluídos dos benefícios do 
screening com doppler transcraniano para avaliação do risco de acidente vascular 
cerebral, apesar de evidência extensa e convincente
Daniela Laranja Gomes Rodrigues1, Samuel Ademola Adegoke2,3, Rejane de Souza Macedo Campos1, 
Josefina Aparecida Pellegrini Braga4, Maria Stella Figueiredo3, Gisele Sampaio Silva1,5
Transcranial doppler (TCD) is a non-invasive ultrasound 
first described by Aaslid et al.1 in 1982 as a means of recording 
blood flow velocities in the basal cerebral arteries. It is relatively 
inexpensive, repeatable and portable, hence it is a more conve-
nient means of monitoring cerebral blood flow velocities and 
vessel pulsatility than other neuroimaging techniques2,3.
1Universidade Federal de São Paulo, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brasil;
2Department of Pediatrics and Child Health, Obafemi Awolowo University, Ile-Ife, Nigeria; 
3Universidade Federal de São Paulo, Departamento de Oncologia Clínica e Experimental, São Paulo SP, Brasil;
4Universidade Federal de São Paulo, Departamento de Pediatria, São Paulo SP, Brasil;
5Hospital Israelita Albert Einstein, Programa Integrado de Neurologia, São Paulo SP, Brasil.
Correspondence: Samuel Ademola Adegoke; Obafemi Awolowo University, Ile-Ife; Nigeria Ile-Ife; PO BOX: 1928, Nigeria; E-mail: adegoke2samade@yahoo.com
Conflict of interest: There is no conflict of interest to declare.
Received 18 March 2016; Received in final form 23 August 2016; Accepted 01 September 2016.
ABSTRACT
Transcranial doppler (TCD) is a strategic component of primary stroke prevention in children with sickle cell disease (SCD). This study was 
conducted to examine the TCD characteristics of children with SCD in nine different medical centers in Brazil. Methods: Transcranial doppler 
was performed in accordance with the Stroke Prevention Trial in Sickle Cell Anemia Protocol. Results: Of the 396 patients, 69.5% had 
homozygous SS hemoglobin. The TCD result was abnormal in 4.8%, conditional in 12.6%, inadequate in 4.3% and abnormally low in 1% of 
patients. The highest mean flow velocities were 121±23.83cm/s and 124±27.21cm/s in the left and right middle cerebral artery respectively. 
A total of 28.8% patients (mean age 9.19±5.92 years) were evaluated with TCD for the first time. Conclusions: The SCD patients were 
evaluated with TCD at an older age, representing an important missed opportunity for stroke prevention. Since TCD screening in patients 
with SCD is important to detect those at high risk for stroke, it is recommended that this screening should be made more readily available.
Keywords: sickle cell disease; ultrasonography, doppler, transcranial; stroke.
RESUMO
Doppler transcraniano (DTC) é um componente estratégico da prevenção primária do acidente vascular cerebral (AVC) em crianças com 
doença falciforme (DF). Este estudo foi realizado para examinar as características do DTC de crianças com DF em nove centros médicos 
diferentes no Brasil. Métodos: DTC foi realizado de acordo com o protocolo de Stroke Prevention Trial in Sickle Cell Anemia Protocol (STOP). 
Resultados: Dos 396 pacientes avaliados, 69,5% eram homozigotos para hemoglobina SS. DTC foi anormal em 4,8%, condicional em 12,6%, 
inadequado em 5,3% e anormalmente baixo em 1%. As máximas velocidades de fluxo médio foram 121 ± 23,83cm/s e 124 ± 27,21 cm/s 
nas artérias cerebrais media esquerda e direita, respectivamente. Um total de 28,8% dos pacientes (média de 9,19 ± 5,92 anos) foram 
avaliados com o DTC pela primeira vez. Conclusões: Pacientes com DF foram avaliados com DTC numa idade considerada avançada, o que 
representa uma importante oportunidade perdida para a prevenção de AVC nessa população. Uma vez que a triagem com DTC em pacientes 
com DF é essencial para detectar aqueles com alto risco de AVC, recomenda-se que essa triagem seja amplamente disponível no país.
Palavras-chave: anemia falciforme; ultrassonografia, doppler transcraniano; acidente vascular cerebral.
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For individuals with sickle cell disease (SCD), TCD is a 
recommended routine screening  test for primary stroke 
prevention, serving as the key test in determining the need 
for chronic blood transfusion. In 2004, Fullerton et al.4 
reported a significant decline in the annual rates of admis-
sions for a first stroke among Californian children with 
SCD following repeated TCD examinations and the imple-
mentation of a blood transfusion program. They found 
that the rate for a first stroke was 0.88/100 person-years in 
1991 – 1998 compared to 0.50/100 person-years in 1999 and 
0.17/100 person-years in 2000.
Despite its usefulness, TCD is highly operator-dependent, 
hence in many countries where TCD facilities are not widely 
available, the examination is unfortunately underutilized2,3. 
This descriptive cross-sectional study was conducted to 
examine the baseline characteristics and TCD results of chil-
dren and adolescents with SCD who were screened in nine 
different medical centers in Brazil.
METHODS
This prospective cross-sectional study was carried out in 
nine medical centers from January 2013 to December 2013 
(see acknowledgements). The patients were chosen by con-
venience method in which all consecutive patients with SCD 
evaluated with TCD during the study period were recruited. 
The study population consisted of children and adolescents 
with SCD who routinely attended the hematology clinic of 
their respective medical center. All the patients were in their 
steady state at the time of the study. Those with fever, acute 
illness, a painful crisis in the preceding four weeks or those 
who had a blood transfusion in the preceding month were not 
included. The study was approved by the Ethics Committee 
and all the participating centers gave their consent before 
starting the registry. 
Demographics and clinical assessment of patients 
with sickle cell disease
Data on epidemiological characteristics (age and sex); 
hydroxyurea therapy, participation in a chronic blood trans-
fusion program; SCD genotype; previous TCD ultrasonogra-
phy data and past history of stroke were collected using a 
semi-structured questionnaire. 
TCD ultrasonography
The mean maximum velocities in the right and left mid-
dle cerebral arteries (MCA) were recorded for each child, 
focussing attention on the highest mean flow velocities, i.e. 
time-averaged mean maximum velocity (TAMM) on either 
side of the MCA. Maximum flow velocity was recorded at an 
insonation depth of 40–60 mm. The findings were catego-
rized as normal (70–169cm/s), conditional (170–199cm/s), 
abnormal (≥ 200cm/s) or abnormally low (< 70cm/s) 
velocities, according to the Stroke Prevention Trial in Sickle 
Cell Anemia Protocol. The frequency of flow velocity asym-
metry defined as an interhemispheric flow velocity difference 
of at least 30 cm/s between segments in the MCAs, was also 
analysed. All TCDs were done by the same author (D.L.R.) 
who visited all the centres during the study period as part of 
a TCD itinerant program in SCD. A 2-MHz pulsed Doppler 
ultrasonograph (Model EME TC 2000, Nicolet, Madison, 
Wisc., USA) was used.
A total of 396 patients with SCD were evaluated in nine 
different medical centres. Two hundred and seven (52.3%) 
were males. The mean age of the patients was 9.97 ± 5.02 years 
with 99 (25.0%) patients in the age group 1-5 years. One hun-
dred and twenty three (31.1%) patients were 6–10 years and 
the remaining 174 (43.9%) were older than 10 years. Most 
patients had hemoglobin SS disease (69.5%). The other gen-
otypes were hemoglobin SC (11.0%); S-b-thalassemia (7.5%); 
and 12.1% with an unknown genotype. Thirteen (3.3%) of 
the 396 patients had a previous history of stroke. One hun-
dred and four patients (26.3%) were using hydroxyurea and 
20 patients (5.1%) were on periodic blood transfusion at the 
time of the screening.
Statistical analysis
Descriptive analyses, including means and standard devi-
ations (SD), were used to describe the patients’ characteris-
tics. The independent samples t test was used to compare 
means between groups. Nonparametric data were compared 
using the Mann- Whitney test. Categorical variables were 
compared with the chi-square test. A two-tailed p-value of 
< 0.05 was considered statistically significant. 
RESULTS
TCD profile of the 396 patients
The TAMM velocity was 121 ± 23.83 cm/s in the left MCA 
and 124 ± 27.21 cm/s in the right MCA. Three hundred and 
six (77.3%) patients had normal TCD velocities. A total of 
69 patients (17.4%) had elevated TCD velocities ≥ 170cm/s; 
of whom 50 (12.6%) had conditional risk velocities of 
170-199cm/s and 19 (4.8%) had abnormal risk velocities of 
≥ 200cm/s. Four patients (1.0%) had abnormally low TCD 
velocities and 17 (4.3%) had inadequate temporal bone win-
dows. Hence, a total of 73 patients had either a conditional, 
abnormally low or abnormal TCD. The frequency of flow 
velocity asymmetry was 7.6%.
Patients with a previous history of stroke had lower TAMM 
velocities in both the right and left MCA than those without a 
previous stroke (113.83 ± 0.8 cm/s versus 124.81 ± 27.4 cm/s, 
p < 0.01; and 116.67 ± 0.3 versus 129.31 ± 21.1 cm/s, p < 0.01, 
respectively). Similarly, those on chronic blood transfusion 
(CBT) had lower TAMM velocities in the right  and left MCA 
(114.92 ± 2.09 cm/s versus 125.01 ± 27.6 cm/s, p<0.01; and 
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107.21 ± 1.22 versus 127.88 ± 4.1 cm/s, p < 0.01, respectively). 
However, there were no differences in blood flow velocities of 
those taking hydroxyurea and those not taking it. 
One hundred and fourteen (28.8%) of the 396 patients were 
evaluated with TCD ultrasonography for the first time during 
the study period. Their mean age was 9.19 ± 5.92 years and 101 
(88.6%) of them were older than two years, the recommended 
age for the first TCD evaluation. Five (4.4%) of the 114 patients 
who were evaluated for the first time had a history of stroke. 
Two (10.5%) of the 19 patients with abnormal risk velocities; 14 
(28.0%) of the 50 with conditional risk velocities; two (50.0%) of 
the four with abnormally low velocities and nine (30.0%) of the 
30 patients with blood flow asymmetry were evaluated for the 
first time with TCD during the study period.
Comparison of the 73 patients with abnormality 
in TCD velocity and the 306 patients with normal 
TCD velocities (excluding the 17 patients with 
inadequate temporal bone windows)
With respect to gender, previous stroke, the use of hydroxy-
urea and being the first TCD evaluation, the proportions of 
patients with normal TCD velocities and those with any abnor-
mality in the TCD velocity (abnormal risk, conditional risk and 
abnormally low velocity) were similar (Table). However, patients 
with abnormality in TCD velocities were younger than those 
with normal TCD velocities (7.71 ± 4.13 versus 10.25 ± 4.94 years, 
p < 0.001), had more flow velocity asymmetry (p = 0.028) and 
were more frequently on chronic blood transfusion (p = 0.012).
DISCUSSION
The cost-effectiveness, portability and repeatability of 
TCD make it an ideal neuroimaging technique, especially for 
patients with SCD who need regular monitoring for primary 
stroke prevention2,5,6. Patients with SCD are at risk for a spec-
trum of brain injuries such as subclinical infarction, acute 
ischemic stroke and hemorrhage due to the high level of cir-
culating irreversibly-sickled red blood cells and their adher-
ence to the vascular endothelium. Hence, SCD patients with 
abnormal TCD velocities should be routinely treated with 
hypertransfusion therapy in order to lower sickle hemoglo-
bin to less than 30% of total haemoglobin7,8.
In this study, about five percent of the SCD patients from 
the nine medical centres had abnormal TCD velocities while 
12.6% had conditional risk velocities. The frequency of asym-
metry was 7.6%. Also, those with any form of TCD abnormal-
ity had more flow velocity asymmetry (p = 0.028) and were 
more frequently on chronic blood transfusion (p = 0.012) than 
those with normal TCD velocities. These findings are consis-
tent with previous reports8,9. In a study evaluating Brazilian 
children with homozygous SS, 1.6% had abnormal TCD 
velocities and none of those with heterozygous SCD had any 
abnormality10. Another Brazilian series also demonstrated 
that TCD velocities of children with SCD from Sergipe, north-
east Brazil, was similar to international standards11.
A total of 13 patients (3.3%) had a previous history of 
stroke. The usefulness of TCD in patients with previous stroke 
is not well established. Patients with SCD and a history of 
stroke should be treated with periodic blood transfusion, 
another factor that could potentially alter TCD results12,13. 
Our study data was collected from practising TCD clinics in 
Brazil. Therefore, the indications for the examinations were 
at the discretion of the treating physicians. The ordering of 
TCD in patients with a previous stroke or on chronic blood 
transfusion reflects some lack of familiarity with the method 
and its indications.
Our study showed that 28.8% of the patients with SCD 
were evaluated with TCD ultrasonography for the first time 
during the study period and had the evaluation at an older 
Table. Comparison of the 73 patients with abnormal, conditional or abnormally low TCD velocities and the 306 patients with 
normal TCD velocities.
Variables Total (n = 379)* Normal TCD velocities (n = 306)
Abnormal, conditional 
or abnormally low TCD  
(n = 73)
p-value
Age (mean ± SD) years 9.77 ± 4.90 10.25 ± 4.94 7.71 ± 4.13 < 0.001
Gender, n (%)
Male 177 139 (45.4) 38 (52.1) 0.308
Female 202 167 (54.6) 35 (47.9)  
Previous stroke 6 5 (1.6) 1 (1.4) 0.125
No previous TCD examination 111 93 (30.4) 18 (24.7) 0.391
Hydroxyurea therapy 102 86 (28.1) 16 (21.9) 0.095
Chronic transfusion therapy 14 9 (2.9) 5 (6.8) 0.012
Flow velocity asymmetry 30 18 (5.9) 12 (16.4) 0.028
SD: Standard deviation; TCD: Transcranial doppler; Normal TCD velocities TAMM: 70–169 cm/s; Conditional TCD velocities TAMM: 170–199 cm/s, Abnormally low 
TCD velocities TAMM < 70 cm/s velocity, Abnormal TCD velcities TAMM ≥ 200 cm/s). TAMM: time-averaged mean maximum velocity - highest mean flow velocities 
on either side of the MCA; *The 17 patients with inadequate windows were not included.
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age (mean age of 9.19 ± 5.92 years). It should be noted that 
88.6% of patients who had TCD for the first time were older 
than two years. This represents a missed opportunity for 
stroke prevention, especially considering the fact that 4.4% 
of them had a past history of stroke and those with TCD 
abnormalities (i.e. those with abnormally low, conditional 
risk or abnormal risk velocities) were significantly younger 
than those with normal TCD velocities, (7.71 ± 4.13 versus 
10.25 ± 4.94 years, p < 0.001). It is also a clear deviation from 
the guideline for TCD screening in SCD children, which rec-
ommends the first evaluation at the age of two years12,13.
Although we did not examine factors responsible for late 
screening in the present study, several causes have been pre-
viously identified. Armstrong-Wells et al, in their report on 
utilization of TCD screening for primary stroke prevention 
in children with SCD, found that proximity to the screening 
center was the only independent predictor of TCD screen-
ing and that children living farther from a vascular laboratory 
were less likely to be screened14. Increased availability of TCD 
screening is therefore imperative to improve the utilization of 
this effective primary stroke prevention strategy.
Our study has some limitations. Firstly, 12.1% of the 
patients did not have a genotype determined in their med-
ical records. This reflects the poor registration of medical 
information in some centers in the country, especially due 
to the lack of use of electronic medical records. Secondly, the 
clinical characterization of the patients with previous stroke 
and the reasons for chronic blood transfusion in our series 
were also not registered, for the same reason. Finally, the 
cross-sectional design of the present registry does not allow 
conclusions on the long-term stroke risk in our patients. 
However, the objective of our study was to describe the char-
acteristics of TCD utilization in SCD patients in the country 
and to point out possible failures in the screening program in 
order to design improvement strategies. Public reporting has 
been associated with better outcomes and the basis for effec-
tive public reporting is the transparency of data15. Therefore, 
even with the above limitations, this study points out impor-
tant gaps in the TCD screening process in patients with SCD 
in our country and can form the basis for redesigning the 
program in Brazil.
In conclusion, despite the extensive and compelling evi-
dence that supports the use of TCD in patients with SCD, 
substantial numbers were excluded from the benefits of this 
intervention in early childhood in the nine centers evaluated. 
In developing countries, this exclusion commonly arises from 
limited access to healthcare facilities, dearth of TCD experts 
and facilities, and insufficient TCD standardization. 
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